About Translation initiation factor eIF2 assembly protein
Translation initiation factor eIF2 assembly protein (CDC123) is a protein
from Homo sapiens identified by UniProt accession
O75794, 336 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | Translation initiation factor eIF2 assembly protein |
|---|
| UniProt accession | O75794 |
|---|
| Gene | CDC123 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 336 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (60)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- FEV/FVC ratio · score 0.38
- type 2 diabetes mellitus · score 0.38
- chronic obstructive pulmonary disease · score 0.37
- forced expiratory volume · score 0.35
- systolic blood pressure · score 0.34
- vital capacity · score 0.34
- electrocardiography · score 0.33
- HbA1c measurement · score 0.32
- diabetes mellitus · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75794-F1 | alphafold | PREDICTED | 84.24 | — |
Amino-acid sequence (336 residues)
MKKEHVLHCQ FSAWYPFFRG VTIKSVILPL PQNVKDYLLD DGTLVVSGRD DPPTHSQPDS DDEAEEIQWS DDENTATLTA PEFPEFATKV QEAINSLGGS VFPKLNWSAP RDAYWIAMNS SLKCKTLSDI FLLFKSSDFI TRDFTQPFIH CTDDSPDPCI EYELVLRKWC ELIPGAEFRC FVKENKLIGI SQRDYTQYYD HISKQKEEIR RCIQDFFKKH IQYKFLDEDF VFDIYRDSRG KVWLIDFNPF GEVTDSLLFT WEELISENNL NGDFSEVDAQ EQDSPAFRCT NSEVTVQPSP YLSYRLPKDF VDLSTGEDAH KLIDFLKLKR NQQEDD
Explore Translation initiation factor eIF2 assembly protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets